Business Wire

Clarity AI Announces Partnership With Aspiration to Deliver Data-Led Climate and Impact Solutions for Consumer Platforms, as Consumer Demand for Sustainability Grows

26.7.2023 15:00:00 EEST | Business Wire | Press release

Share

Clarity AI, the leading sustainability tech platform announces it has partnered with Aspiration, a top global climate finance company, to launch sustainability assessment solutions for consumer use cases. This unique partnership will deliver effective and accessible solutions to consumer platforms (e.g. e-commerce, retail banks, supermarkets, etc.) to help end users measure and reduce their carbon footprint and understand the sustainability performance of merchants by combining Clarity AI’s high-quality, transparent data and tools with Aspiration’s best-in-class carbon removal projects.

How the climate solution works

Customers will be able to assess the sustainability of the brands they buy and their current spending habits based on Clarity AI’s personalized data tracking and AI capabilities – helping them to identify ways to positively change their purchasing patterns.

Clarity AI’s technology will also provide sustainability insights at the individual retailer level. Leveraging its coverage of over 40,000 companies and more than 160 industries (the broadest in the market), Clarity AI calculates the impact of a consumer’s spending and helps them understand company-specific sustainability information rather than broad, industry-level spending trends. It also provides recommendations on how consumers can maximize the impact of their purchases and actions.

Based on this data, Aspiration will offer customers the opportunity to mitigate their carbon footprint by purchasing credits from high-quality, nature-based climate solutions that are rigorously vetted to deliver real, tangible impact that contributes toward the path to net zero.

Aspiration will also offer customers the opportunity to contribute to carbon removal projects with benefits beyond climate impact such as biodiversity improvements and job creation for underrepresented communities. This approach allows users to support projects that align with their values in broader environmental and social dimensions.

High customer demand for carbon data on purchases and mitigation strategies can be met with high-quality carbon credits

During a recent Clarity AI-hosted event for over 900 global brands (including Citigroup, eBay, and Target), companies revealed which sustainability metrics were most important to their customers.

Amongst the food and beverage, fashion, and electronics sectors – which accounted for 65% of responses – carbon emissions were the most critical metric, with 60% of respondents saying that their customers wanted to see this information. Additionally, 87% of attendees believed sustainability information about consumers’ purchases will be a must-have before 2030, with 44% of them believing it will be a must-have by 2025.

This consumer demand for quality sustainability information is increasing in line with the number of tools available to support sustainability projects, including carbon removals – between 2020 and 2021 the carbon market saw year-on-year growth of 164%.

However, rigorous quality control is critical to driving impact. Aspiration implements best-in-class standards when it comes to vetting carbon removal and avoidance projects – on average, less than one in five projects Aspiration reviews through its diligence process make it into its pipeline of approved projects.

This solution from Clarity AI and Aspiration aims to empower customers to understand the impact of their purchasing decisions and the opportunity for them to take effective action.

Rebeca Minguela, Founder & CEO of Clarity AI commented: “We believe that customers need and want to act, and they need data and tools to do so. They need to seamlessly see the carbon footprint of their purchases and trust that information. Then they need to easily offset those and get recommendations on how to maximize their impact going forward. Partnering with Aspiration, we can satisfy all those criteria and help consumers find a path to a more sustainable future.”

Olivia Albrecht, CEO of Aspiration commented: “The best way to transition to a low-carbon economy is for businesses, consumers, and communities to work collectively to achieve climate goals. The solution we're providing through our collaboration with Clarity AI is all about giving consumers access to climate data and the tools to take action right at their fingertips via their mobile apps.”

About Clarity AI
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. Clarity AI’s capabilities are an essential tool for end-to-end sustainability analysis related to investing, corporate research, benchmarking, consumer e-commerce, and regulatory reporting. As of June 2023, Clarity AI’s platform analyzes more than 70,000 companies, 420,000 funds, 201 countries, and 199 local governments, which represents more breadth than any other player in the market. One way Clarity AI delivers on its mission to bring societal impact to markets is by ensuring its capabilities are delivered directly into clients' workflows through integrations with partners like BlackRock - Aladdin, Refinitiv an LSEG business, BNP Manaos, CACEIS, and SimCorp. Additionally, Clarity AI's sustainability insights reach more than 150 million consumers across more than 400,000 merchants. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets and includes companies like Invesco, Nordea, BlackRock, Santander, Wellington, and BNP Paribas.

About Aspiration
Aspiration Partners is a high-impact climate finance company working at scale to help enterprises, consumers, and investors achieve their climate goals. Founded in 2013, the company sources, monitors, and invests in carbon removal projects across the globe to generate high-quality carbon credits. Every project in Aspiration's portfolio is held to the most rigorous standards, ensuring each drives tangible, positive impact for people and the planet. Aspiration is a certified B Corp, a member of Project Drawdown, 1t.org, Climate Pledge and many other critical industry groups dedicated to accelerating climate action. For more information, visit Aspiration.com or Aspiration.com/business.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Edelman
clarityAI@edelmansmithfield.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye